Valuation: Pluristem Therapeutics

Market Cap 2.26Cr 1.98Cr 1.83Cr 1.69Cr 3.19Cr 215.83Cr 3.25Cr 22Cr 8.56Cr 105.99Cr 8.47Cr 8.28Cr 366.04Cr P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 3.6Cr 3.16Cr 2.92Cr 2.69Cr 5.09Cr 344.44Cr 5.19Cr 35Cr 14Cr 169.15Cr 14Cr 13Cr 584.15Cr EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.43%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 43 02/10/2003
Director/Board Member 54 01/02/2015
Chairman 68 04/12/2025
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 1.85Cr
+0.44%+2.51%+4.36%+10.27% 5.07TCr
-1.57%-3.18%+383.82%+593.37% 3.97TCr
-0.14%+0.77%+27.49%-5.50% 3.47TCr
+1.76%-1.78%+21.44%+53.38% 3.32TCr
-0.06%-4.63%+2.94%+31.65% 2.68TCr
-1.93%-1.01% - - 1.68TCr
-1.49%-6.18%+63.89%+120.53% 1.54TCr
+0.78%+1.16%+14.69%+17.32% 1.38TCr
-0.97%-2.83%+10.35%-33.29% 1.28TCr
Average +0.02%-0.98%+66.12%+98.47% 2.71TCr
Weighted average by Cap. -0.18%-0.38%+81.60%+124.11%

Financials

2024 2025
Net sales 3L 3L 3L 2L 5L 3.12Cr 5L 31.56L 12.38L 1.53Cr 12.24L 11.97L 5.29Cr 13.36L 11.72L 10.85L 10L 18.89L 13Cr 19.26L 1.29Cr 50.73L 6.28Cr 50.17L 49.07L 22Cr
Net income -2.09Cr -1.83Cr -1.7Cr -1.56Cr -2.95Cr -199.92Cr -3.01Cr -20Cr -7.93Cr -98Cr -7.84Cr -7.67Cr -339.06Cr -2.26Cr -1.98Cr -1.83Cr -1.69Cr -3.19Cr -216.15Cr -3.25Cr -22Cr -8.58Cr -106.15Cr -8.48Cr -8.29Cr -366.57Cr
Net Debt -4L -3L -3L -3L -5L -3.57Cr -5L -36.11L -14.16L -1.75Cr -14.01L -13.7L -6.05Cr 1.34Cr 1.18Cr 1.09Cr 1Cr 1.9Cr 128.61Cr 1.94Cr 13Cr 5.1Cr 63Cr 5.05Cr 4.94Cr 218.11Cr
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-